Table 3.
Prevalence of non-cavity-distorting fibroid and largest fibroid volume between study patients.
| Non-cavity- distorting fibroids- no./total no. (%) |
P valuea | Non-cavity-distorting fibroids with any dimension >=4 cm- no./total no. (%)b |
P valuea | Largest fibroid volume (cm3)-median (IQR)b |
P valuec | |
|---|---|---|---|---|---|---|
| Patient group | <0.001 | 0.66 | 0.78 | |||
| PCOS | 92/1371 (6.7) | 14/746 (1.9) | 6.4 (1.2 – 26.6), n=48 | |||
| UI | 109/878 (12.4) | 14/878 (1.6) | 7.6 (1.7 – 29.0), n=99 | |||
| Race | ||||||
| Black | <0.001 | 1.00 | 0.26 | |||
| PCOS | 22/206 (10.7) | 5/98 (5.1) | 40.8 (8.8 – 78.3), n=7 | |||
| UI | 28/78 (35.9) | 4/78 (5.1) | 15.6 (6.4 – 31.2), n=26 | |||
| Non-Black | 0.001 | 0.82 | 0.69 | |||
| PCOS | 70/1165 (6.0) | 9/648 (1.4) | 4.9 (1.0 – 22.4), n=41 | |||
| UI | 81/800 (10.1) | 10/800 (1.3) | 4.4 (1.6 – 19.1), n=73 | |||
| BMI (kg/m2) | ||||||
| <25 | <0.001 | 0.59 | 0.89 | |||
| PCOS | 6/214 (2.8) | 0/119 (0) | 4.1 (1.7 – 6.4), n=2 | |||
| UI | 45/425 (10.6) | 5/425 (1.2) | 3.1 (1.1–19.1), n=42 | |||
| 25–29 | 0.02 | 0.42 | ||||
| PCOS | 12/209 (5.7) | 1/125 (0.8) | 8.0 (1.7 – 20.7), n=6 | 0.83 | ||
| UI | 28/218 (12.8) | 5/218 (2.3) | 12.0 (2.1 – 29.0), n=26 | |||
| >=30 | <0.001 | 0.60 | 0.30 | |||
| PCOS | 74/947 (7.8) | 13/502 (2.6) | 7.6 (1.1 – 34.1), n=40 | |||
| UI | 36/235 (15.3) | 4/235 (1.7) | 11.5 (2.6 – 38.1), n=31 |
a
Chi-square or Fisher’s exact test was used.
b
For patients from PPCOS II and AMIGOS studies only.
c
A Wilcoxon rank sum test was used.